ArticleSouth Asian journal of cancer2025
Oncological Safety and Feasibility of Posterior Marginal Mandibulectomy vis-à-vis Anterior Marginal Mandibulectomy in Oral Cancers.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Marginal Mandibulectomy in Oral Cavity Cancers - Classification and Indications.Indian journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The surgical management of retromolar trigone cancer (RTC) is an area of contention regarding the extent of bony resection. We aim to evaluate the oncological safety and feasibility of posterior marginal mandibulectomy (PMM) for RTC. We analyzed the clinical records of 98 patients with squamous cell carcinoma managed surgically using marginal mandibulectomy during 2014 to 2017, in which anterior segment mandibulectomy (AMM) and PMM were done in 56 and 42 patients, respectively. The median follow-up time was 44.4 months (95% confidence interval [CI] 42.3, 49.5) and the overall survival rate was 93.9% (95% CI 89.4-98.8%). The local recurrence rate was 19.6 and 18.3 % in PMM and AMM (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.